Topic: Life sciences and healthcare

A Pennsylvania state board has filed a groundbreaking lawsuit against the company behind Character.AI, alleging that an artificial intelligence chatbot's claims of psychiatric credentials and a Pennsylvania medical license constitute the unlicensed practice of medicine.

Colorado just rewrote its own AI regulation, affecting every company developing or deploying AI in a way that may touch a Colorado resident.

Colorado's landmark AI act is officially on ice, and the legal fight behind that development is shaping the national conversation on AI regulation.

Norton Rose Fulbright lawyers authored and edited key chapters in Digital Health 2026, covering artificial intelligence, the bio industrial technology stack and emerging technologies.

Healthcare providers are rapidly adopting AI for clinical and operational uses, often involving protected health information that is governed by HIPAA’s Privacy Rule.

As recent innovations in Artificial Intelligence (“AI”) such as ChatGPT ignite debate over issues such as the legal status of non-humans, privacy implications of novel computing abilities, and rights of intelligent systems’ creators over output, similar considerations confront another emerging computing field—one involving human cells.

The European Commission (along with the US FTC and DOJ, UK CMA, German FCO and others), has been focused on ensuring that so-called “killer acquisitions” in the digital and life sciences sectors are reviewed. Against this background, the General Court’s decision in Illumina/Grail is of key importance to companies acquiring start-ups.

As the telemedicine industry continues to grow, especially in light of COVID-19, businesses should reconsider their policies and procedures in connection with telehealth services and user safety.